HK1170482A1 - Apoptosis signal-regulating kinase inhibitors - Google Patents
Apoptosis signal-regulating kinase inhibitorsInfo
- Publication number
- HK1170482A1 HK1170482A1 HK12111231.2A HK12111231A HK1170482A1 HK 1170482 A1 HK1170482 A1 HK 1170482A1 HK 12111231 A HK12111231 A HK 12111231A HK 1170482 A1 HK1170482 A1 HK 1170482A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- apoptosis signal
- regulating kinase
- regulating
- apoptosis
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22507609P | 2009-07-13 | 2009-07-13 | |
US22507909P | 2009-07-13 | 2009-07-13 | |
US28926309P | 2009-12-22 | 2009-12-22 | |
PCT/US2010/041739 WO2011008709A1 (en) | 2009-07-13 | 2010-07-12 | Apoptosis signal-regulating kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1170482A1 true HK1170482A1 (en) | 2013-03-01 |
Family
ID=42670422
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12111231.2A HK1170482A1 (en) | 2009-07-13 | 2012-11-07 | Apoptosis signal-regulating kinase inhibitors |
HK16104397.3A HK1216426A1 (zh) | 2009-07-13 | 2016-04-18 | 凋亡信號調節激酶抑制劑 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16104397.3A HK1216426A1 (zh) | 2009-07-13 | 2016-04-18 | 凋亡信號調節激酶抑制劑 |
Country Status (28)
Country | Link |
---|---|
US (7) | US8378108B2 (xx) |
EP (4) | EP2454250B1 (xx) |
JP (4) | JP5745721B2 (xx) |
KR (3) | KR20180077338A (xx) |
CN (1) | CN102482257B (xx) |
AR (1) | AR077564A1 (xx) |
AU (1) | AU2010273597B2 (xx) |
BR (1) | BR112012000894A2 (xx) |
CA (1) | CA2767894C (xx) |
CY (1) | CY1119889T1 (xx) |
DK (2) | DK2933252T3 (xx) |
ES (3) | ES2854710T3 (xx) |
HK (2) | HK1170482A1 (xx) |
HR (2) | HRP20150185T1 (xx) |
HU (1) | HUE038529T2 (xx) |
LT (1) | LT2933252T (xx) |
ME (1) | ME02104B (xx) |
MX (1) | MX2012000708A (xx) |
NO (1) | NO2933252T3 (xx) |
NZ (1) | NZ597533A (xx) |
PL (3) | PL2454250T3 (xx) |
PT (3) | PT2933252T (xx) |
RS (2) | RS56981B1 (xx) |
SI (3) | SI2933252T1 (xx) |
SM (1) | SMT201500090B (xx) |
TW (3) | TWI491606B (xx) |
UY (1) | UY32786A (xx) |
WO (1) | WO2011008709A1 (xx) |
Families Citing this family (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102238950B (zh) | 2008-08-04 | 2014-05-07 | Chdi基金会股份有限公司 | 某些犬尿氨酸-3-单加氧酶抑制剂、药物组合物以及使用方法 |
TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
JP2013518046A (ja) | 2010-01-25 | 2013-05-20 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | 特定のキヌレニン−3−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
AU2011272782B2 (en) * | 2010-07-02 | 2014-11-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ask1阻害ピロロピリミジン誘導体 |
BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
HUE034802T2 (en) * | 2011-08-30 | 2018-02-28 | Chdi Foundation Inc | Kinurenin-3-monooxygenase inhibitors, pharmaceutical preparations and methods of use |
AU2015201188B2 (en) * | 2012-01-27 | 2016-12-15 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitor |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
WO2014100755A2 (en) | 2012-12-20 | 2014-06-26 | Biomatrica, Inc. | Formulations and methods for stabilizing pcr reagents |
UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
CA2897651C (en) | 2013-01-10 | 2021-09-21 | Pulmokine, Inc. | Non-selective kinase inhibitors |
EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
WO2015002729A2 (en) | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Cell stabilization |
US9249151B2 (en) * | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
CN111743901B (zh) | 2013-10-11 | 2023-09-12 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
WO2015070366A1 (en) * | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
CA2931615A1 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CA2937320A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
US20150342943A1 (en) | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
CN113826612B (zh) | 2014-06-10 | 2022-11-22 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
CN114588157A (zh) | 2014-07-17 | 2022-06-07 | Chdi基金会股份有限公司 | 用于治疗hiv相关病症的方法和组合物 |
TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
CN106714841A (zh) | 2014-09-24 | 2017-05-24 | 吉利德科学公司 | 治疗肝病的方法 |
MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
CN107108519B (zh) | 2014-12-23 | 2020-11-03 | 吉利德科学公司 | 制备ask1抑制剂的方法 |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
RS56787B1 (sr) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina |
EP3456717B1 (en) | 2015-07-06 | 2021-03-17 | Gilead Sciences, Inc. | 4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease |
CA2991765C (en) * | 2015-07-09 | 2023-10-03 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as glun2b receptor modulators |
KR200483190Y1 (ko) | 2015-09-11 | 2017-04-13 | 주식회사 엔젤악기 | 바로크식 운지법과 독일식 운지법의 선택 적용이 가능한 리코더 링 |
JP2018530550A (ja) | 2015-10-01 | 2018-10-18 | ギリアド サイエンシズ, インコーポレイテッド | 癌を治療するためのbtk阻害剤とチェックポイント阻害剤との組合せ |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP4242628A3 (en) | 2015-12-08 | 2023-11-08 | Biomatrica, INC. | Reduction of erythrocyte sedimentation rate |
AU2016370916A1 (en) | 2015-12-17 | 2018-06-07 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
ES2916874T3 (es) * | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
US20170174679A1 (en) | 2015-12-22 | 2017-06-22 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP2019510752A (ja) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ, インコーポレイテッド | オートタキシン阻害剤の組成物及び合剤 |
JP2019513700A (ja) | 2016-03-16 | 2019-05-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺有害生物剤及び植物保護剤としてのn−(シアノベンジル)−6−(シクロプロピル−カルボニルアミノ)−4−(フェニル)−ピリジン−2−カルボキサミド誘導体及び関連する化合物 |
JP2019513737A (ja) | 2016-04-08 | 2019-05-30 | ギリアード サイエンシーズ, インコーポレイテッド | がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法 |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
CA3027209C (en) | 2016-06-13 | 2022-08-16 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
CA3035346A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018081567A1 (en) | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
KR20190083655A (ko) | 2016-11-11 | 2019-07-12 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하는 방법 |
WO2018090869A1 (zh) * | 2016-11-16 | 2018-05-24 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
WO2018097977A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
WO2018098367A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
CA3047980A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
MX2019007416A (es) | 2016-12-22 | 2019-12-11 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
CN109071538B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | 作为ask1抑制剂的吡啶衍生物及其制备方法和应用 |
JP7206193B2 (ja) | 2017-01-24 | 2023-01-17 | アイ-エムエービー バイオファーマ ユーエス リミテッド | 抗cd73抗体およびその使用 |
ES2926449T3 (es) | 2017-02-07 | 2022-10-26 | Biogen Ma Inc | Agentes inhibidores de ASK1 |
EP3585789A1 (en) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
TWI754011B (zh) | 2017-02-24 | 2022-02-01 | 美商基利科學股份有限公司 | 布魯頓氏酪胺酸激酶之抑制劑 |
WO2018157277A1 (en) * | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
KR20190126322A (ko) * | 2017-03-03 | 2019-11-11 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 아미드 유도체 억제제 및 그의 제조 방법 및 적용 |
JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
WO2018183122A1 (en) * | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
US20180311244A1 (en) | 2017-03-28 | 2018-11-01 | Gilead Sciences, Inc. | Methods of treating liver disease |
JOP20190221A1 (ar) | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها |
TW201902478A (zh) | 2017-04-12 | 2019-01-16 | 美商基利科學股份有限公司 | 治療肝臟疾病之方法 |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
KR102629267B1 (ko) * | 2017-05-12 | 2024-01-25 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나아제 1 억제제 및 이의 사용 방법 |
US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2018218044A2 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2018218051A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN110770233B (zh) * | 2017-06-19 | 2022-07-26 | 广东东阳光药业有限公司 | 稠合双环类化合物及其在药物中的应用 |
GB201711234D0 (en) * | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
CN109265443B (zh) * | 2017-07-18 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
EP3284739A1 (de) | 2017-07-19 | 2018-02-21 | Bayer CropScience Aktiengesellschaft | Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel |
WO2019034096A1 (en) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE |
US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109456308B (zh) * | 2017-09-06 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
CN111315380A (zh) * | 2017-09-08 | 2020-06-19 | 弗朗塞拉美国制药有限责任公司 | 凋亡信号调节激酶抑制剂及其用途 |
CN111518080A (zh) * | 2017-10-12 | 2020-08-11 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
CN107793400B (zh) * | 2017-10-31 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用 |
WO2019099307A1 (en) * | 2017-11-17 | 2019-05-23 | Hepagene Therapeutics, Inc. | Urea derivatives as inhibitors of ask1 |
CN109956928B (zh) * | 2017-12-14 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物、其制备方法及用途 |
CA3084569A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN111801314B (zh) * | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
WO2019134680A1 (zh) * | 2018-01-05 | 2019-07-11 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
KR102586510B1 (ko) | 2018-02-13 | 2023-10-12 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
CN110294746B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 一种新的ask1抑制剂及其应用 |
CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
JP7372255B2 (ja) | 2018-03-30 | 2023-10-31 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
WO2019200267A1 (en) | 2018-04-12 | 2019-10-17 | Terns, Inc. | Tricyclic ask1 inhibitors |
WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
EP3787621A4 (en) * | 2018-05-02 | 2022-01-12 | Enanta Pharmaceuticals, Inc. | APOPTOSIS SIGNAL REGULATING KINASE 1 INHIBITORS CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
CA3098873A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
DK3793565T3 (en) | 2018-05-14 | 2022-03-07 | Gilead Sciences Inc | Mcl-1-inhibitorer |
MA53009A (fr) * | 2018-06-27 | 2021-05-05 | Biogen Ma Inc | Agents inhibiteurs d'ask1 |
WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
CN112638912B (zh) * | 2018-07-20 | 2022-04-26 | 福建广生中霖生物科技有限公司 | 作为ask1抑制剂的晶型及其制备方法和应用 |
WO2020030107A1 (zh) * | 2018-08-10 | 2020-02-13 | 江苏豪森药业集团有限公司 | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 |
CN110818683B (zh) * | 2018-08-10 | 2023-04-14 | 中国科学院上海药物研究所 | 2-吡啶取代脲结构小分子化合物及其合成和应用 |
CN111132984A (zh) * | 2018-08-14 | 2020-05-08 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶1抑制剂的盐及其晶型 |
JP2021534152A (ja) * | 2018-08-14 | 2021-12-09 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Ask1阻害剤 |
MA53223A (fr) | 2018-08-14 | 2022-04-27 | Biogen Ma Inc | Composés macrocycliques de pyridine en tant qu'agents inhibiteurs d'ask1 |
WO2020041417A1 (en) * | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US20210213006A1 (en) * | 2018-08-29 | 2021-07-15 | Seal Rock Therapeutics, Inc. | Methods of treating neurodegenerative diseases |
WO2020063727A1 (zh) * | 2018-09-30 | 2020-04-02 | 山东轩竹医药科技有限公司 | 三并环类ask1抑制剂及其应用 |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109608441A (zh) * | 2018-12-26 | 2019-04-12 | 都创(上海)医药科技有限公司 | 一种ask1抑制剂的合成工艺 |
CR20210385A (es) | 2019-01-15 | 2021-09-14 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
KR20210137518A (ko) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
AU2020234929B2 (en) | 2019-03-11 | 2023-09-14 | Gilead Sciences, Inc. | Formulations of a compound and uses thereof |
US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
CA3155852A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
CA3175541A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
TWI778562B (zh) | 2020-04-02 | 2022-09-21 | 美商基利科學股份有限公司 | 製備cot抑制劑化合物的方法 |
WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
JP7490088B2 (ja) | 2020-06-03 | 2024-05-24 | ギリアード サイエンシーズ, インコーポレイテッド | Lpa受容体アンタゴニスト及びその使用 |
US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
JP2024512646A (ja) | 2021-03-29 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | Khk阻害剤 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療fxr誘發之搔癢之il-31調節劑 |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024059216A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
WO2024059212A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
CA1121825A (en) | 1978-04-11 | 1982-04-13 | Franco Bolasco | 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
WO1998034946A1 (en) | 1997-02-12 | 1998-08-13 | Massachusetts Institute Of Technology | Daxx, a novel fas-binding protein that activates jnk and apoptosis |
AUPP285898A0 (en) * | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
AU782448B2 (en) | 1999-03-19 | 2005-07-28 | Aventis Pharmaceuticals Inc. | Akt nucleic acids, polypeptides, and uses thereof |
US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
US20040087798A1 (en) * | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
JPWO2002038179A1 (ja) * | 2000-11-10 | 2004-03-11 | キッセイ薬品工業株式会社 | 小胞体ストレス関連疾患の予防又は治療剤 |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
TW200400963A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
TW200400818A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
WO2005009470A1 (ja) | 2003-07-28 | 2005-02-03 | Osaka Industrial Promotion Organization | Ask1阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法 |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
US8101770B2 (en) * | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
WO2008042867A2 (en) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
EP2104734A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
US8263595B2 (en) | 2007-08-31 | 2012-09-11 | Merck Serono Sa | Triazolopyridine compounds and their use as ask inhibitors |
EP2227471A1 (en) | 2007-12-11 | 2010-09-15 | Schering Corporation | Gamma secretase modulators |
EP2271646A1 (en) | 2008-03-31 | 2011-01-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
WO2010008843A1 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
US20110263441A1 (en) | 2008-10-15 | 2011-10-27 | Golub Todd R | Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders |
US20110294693A1 (en) | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
ES2445917T3 (es) | 2010-02-03 | 2014-03-06 | Takeda Pharmaceutical Company Limited | Inhibidores de quinasa 1 reguladora de la señal de apoptosis |
WO2011097594A2 (en) | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Therapeutic methods and compositions involving allosteric kinase inhibition |
KR20180032686A (ko) | 2010-03-24 | 2018-03-30 | 아미텍 테러퓨틱 솔루션즈 인크 | 인산화효소 억제에 유용한 헤테로환 화합물 |
AU2011272782B2 (en) | 2010-07-02 | 2014-11-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
WO2012054510A1 (en) | 2010-10-19 | 2012-04-26 | Comentis, Inc. | Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof |
US20130236441A1 (en) | 2010-11-18 | 2013-09-12 | University Of Delaware | Methods of treating and preventing thrombotic diseases using ask1 inhibitors |
JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ask1阻害ピロロピリミジン誘導体 |
WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
EP2718721A4 (en) | 2011-06-07 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS FOR CANCER |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
HUE037444T2 (hu) | 2011-11-11 | 2018-09-28 | Gilead Apollo Llc | ACC inhibitorok és azok felhasználása |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
UY35212A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
AP2016009248A0 (en) | 2013-12-20 | 2016-05-31 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitors |
CN103896990B (zh) | 2014-03-12 | 2017-02-08 | 石家庄诚志永华显示材料有限公司 | 有机电致发光材料及其应用 |
US20150342943A1 (en) | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
CN106714841A (zh) * | 2014-09-24 | 2017-05-24 | 吉利德科学公司 | 治疗肝病的方法 |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
CN107108519B (zh) | 2014-12-23 | 2020-11-03 | 吉利德科学公司 | 制备ask1抑制剂的方法 |
MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
WO2016112305A1 (en) | 2015-01-09 | 2016-07-14 | Nimbus Apollo, Inc. | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
CA3172549A1 (en) | 2016-03-02 | 2017-09-08 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
PL3730487T3 (pl) | 2016-06-13 | 2022-08-16 | Gilead Sciences, Inc. | Pochodne azetydyny jako modulatory fxr (nr1h4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
KR20190083655A (ko) | 2016-11-11 | 2019-07-12 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하는 방법 |
JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
US20180311244A1 (en) | 2017-03-28 | 2018-11-01 | Gilead Sciences, Inc. | Methods of treating liver disease |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
TW201902478A (zh) | 2017-04-12 | 2019-01-16 | 美商基利科學股份有限公司 | 治療肝臟疾病之方法 |
JP7479278B2 (ja) | 2017-10-06 | 2024-05-08 | ギリアード サイエンシーズ, インコーポレイテッド | Acc阻害剤を含む併用療法 |
-
2010
- 2010-07-06 TW TW099122220A patent/TWI491606B/zh active
- 2010-07-06 TW TW104112851A patent/TWI598347B/zh active
- 2010-07-06 TW TW106124595A patent/TWI625121B/zh active
- 2010-07-12 ES ES17208659T patent/ES2854710T3/es active Active
- 2010-07-12 MX MX2012000708A patent/MX2012000708A/es active IP Right Grant
- 2010-07-12 SI SI201031622T patent/SI2933252T1/en unknown
- 2010-07-12 RS RS20180292A patent/RS56981B1/sr unknown
- 2010-07-12 PT PT151510302T patent/PT2933252T/pt unknown
- 2010-07-12 SI SI201032055T patent/SI3363797T1/sl unknown
- 2010-07-12 EP EP10733116.7A patent/EP2454250B1/en active Active
- 2010-07-12 PL PL10733116T patent/PL2454250T3/pl unknown
- 2010-07-12 RS RS20150247A patent/RS53951B1/en unknown
- 2010-07-12 AR ARP100102515A patent/AR077564A1/es active IP Right Grant
- 2010-07-12 AU AU2010273597A patent/AU2010273597B2/en active Active
- 2010-07-12 NO NO15151030A patent/NO2933252T3/no unknown
- 2010-07-12 ME MEP-2015-53A patent/ME02104B/me unknown
- 2010-07-12 EP EP20210819.7A patent/EP3858824A1/en active Pending
- 2010-07-12 CA CA2767894A patent/CA2767894C/en active Active
- 2010-07-12 JP JP2012520706A patent/JP5745721B2/ja active Active
- 2010-07-12 PT PT172086597T patent/PT3363797T/pt unknown
- 2010-07-12 WO PCT/US2010/041739 patent/WO2011008709A1/en active Application Filing
- 2010-07-12 EP EP15151030.2A patent/EP2933252B1/en active Active
- 2010-07-12 KR KR1020187018679A patent/KR20180077338A/ko not_active Application Discontinuation
- 2010-07-12 HU HUE15151030A patent/HUE038529T2/hu unknown
- 2010-07-12 SI SI201030851T patent/SI2454250T1/sl unknown
- 2010-07-12 EP EP17208659.7A patent/EP3363797B8/en active Active
- 2010-07-12 KR KR1020127000966A patent/KR101755524B1/ko active IP Right Grant
- 2010-07-12 NZ NZ597533A patent/NZ597533A/en unknown
- 2010-07-12 ES ES15151030T patent/ES2662397T3/es active Active
- 2010-07-12 BR BR112012000894A patent/BR112012000894A2/pt not_active Application Discontinuation
- 2010-07-12 ES ES10733116.7T patent/ES2533796T3/es active Active
- 2010-07-12 PL PL17208659T patent/PL3363797T3/pl unknown
- 2010-07-12 DK DK15151030.2T patent/DK2933252T3/en active
- 2010-07-12 PL PL15151030T patent/PL2933252T3/pl unknown
- 2010-07-12 LT LTEP15151030.2T patent/LT2933252T/lt unknown
- 2010-07-12 CN CN201080040457.5A patent/CN102482257B/zh active Active
- 2010-07-12 KR KR1020177018101A patent/KR20170081722A/ko not_active Application Discontinuation
- 2010-07-12 DK DK10733116T patent/DK2454250T3/en active
- 2010-07-12 US US12/834,673 patent/US8378108B2/en active Active
- 2010-07-12 PT PT107331167T patent/PT2454250E/pt unknown
- 2010-07-13 UY UY0001032786A patent/UY32786A/es not_active Application Discontinuation
-
2012
- 2012-09-13 US US13/615,259 patent/US8552196B2/en not_active Ceased
- 2012-09-14 US US13/618,841 patent/US8598360B2/en active Active
- 2012-11-07 HK HK12111231.2A patent/HK1170482A1/xx unknown
-
2013
- 2013-07-02 US US13/934,020 patent/US9067933B2/en active Active
-
2015
- 2015-02-17 HR HRP20150185AT patent/HRP20150185T1/hr unknown
- 2015-03-03 JP JP2015040924A patent/JP2015098500A/ja not_active Withdrawn
- 2015-04-13 SM SM201500090T patent/SMT201500090B/xx unknown
- 2015-05-19 US US14/716,526 patent/US9586932B2/en active Active
-
2016
- 2016-04-18 HK HK16104397.3A patent/HK1216426A1/zh unknown
-
2017
- 2017-01-19 JP JP2017007269A patent/JP2017071647A/ja not_active Withdrawn
- 2017-01-23 US US15/413,101 patent/US20170196844A1/en not_active Abandoned
-
2018
- 2018-03-07 CY CY20181100283T patent/CY1119889T1/el unknown
- 2018-03-09 HR HRP20180413TT patent/HRP20180413T1/hr unknown
- 2018-08-01 JP JP2018144888A patent/JP2018184464A/ja active Pending
-
2019
- 2019-08-01 US US16/529,631 patent/USRE48711E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216426A1 (zh) | 凋亡信號調節激酶抑制劑 | |
IL247405A0 (en) | Apoptosis signal-regulating kinase inhibitors | |
HK1179477A1 (en) | Kinase inhibitors | |
PL2531501T3 (pl) | Inhibitory kinazy 1 regulującej sygnał apoptotyczny | |
ZA201203842B (en) | Kinase inhibitors | |
EP2558099A4 (en) | Kinase Inhibitors | |
IL220212A0 (en) | Aminopyrimidine kinase inhibitors | |
EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
EP2406236A4 (en) | INHIBITORS OF RHO KINASE | |
EP2519517A4 (en) | TYPE II RAF KINASE INHIBITORS | |
ZA201108048B (en) | P38map kinase inhibitor | |
EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
GB201009731D0 (en) | Kinase inhibitors | |
EP2396004A4 (en) | SELECTIVE KINASE HEMMER | |
EP2702064A4 (en) | Kinase Inhibitors | |
ZA201205277B (en) | Sphingosine kinase inhibitors | |
ZA201205237B (en) | Sphingosine kinase inhibitors | |
GB0901898D0 (en) | Dual calpain-ros inhibitors | |
EP2480076A4 (en) | IMIDAZOTHIAZOLIC INHIBITORS OF KINASES | |
GB0914726D0 (en) | Kinase inhibitors | |
GB0901900D0 (en) | Dual calpain-ros inhibitors | |
GB0902661D0 (en) | Inhibitors | |
GB0903650D0 (en) | Glyoalase inhibitors | |
GB201009730D0 (en) | Kinase inhibitor compounds |